U.K. Drug for Abuse Testing Devices Market, by Product Type (Immunoassay Analyzers, Chromatography Instruments, Breathalyzers (Semiconductor-based Breathalyzer, Infrared (IR) Based Breathalyzer, and Fuel Cell-based Breathalyzer), Oral Fluid Testing Devices, Urine Testing Devices (Drug Testing Cup, DIP Cards, and Drug Testing Cassettes) , and Consumables (Assay Kits, Calibrators and Controls, and Others)), by Sample Type (Urine, Breathe, Saliva, Hair, and Others), and by End User (Hospitals, Federal Departments, Rehabilitation Centers, Diagnostic Laboratories, Academic Institutes and Research Centers, and Others), published by Coherent Market Insights.
U.K drug for abuse testing devices market is expected to surpass US$ 389.1 million by 2027, exhibiting a CAGR of 5.0% during the forecast period (2020-2027). The rising prevalence of drunk and drive cases and drug addiction are major factors that are expected to boost the U.K. drug for abuse testing devices market growth. For instance, according to the Home Office Crime Survey for England and Wales report published in September 2019, around one in 11 (9.4%) adults aged 16-59 had taken a drug in 2017-2018, which equated to around 3.2 million people. According to the same source, around one in 5 (20.3%) adults aged 16 -24 had taken a drug in 2017-2018.
U.K. Drug for Abuse Testing Devices – Impact of Coronavirus (COVID-19) Pandemic
Drug for abuse testing devices are used for alcohol detection and drug detection. Some of the devices used for alcohol and drugs testing include Breathalyzer, intoxilyzer, Alco-sensor, and oral fluid testing devices. These devices are used in various sectors such as hospitals, rehabilitation centers, federal departments, construction, transportation, and private sector. COVID-19 crisis has significantly disrupted all the supply chains of these devices. The pandemic's impact has been overwhelmingly negative in many areas, the MedTech industry has experienced both ups and downs throughout the crisis. Manufacturers of medical devices also suffered due to the pandemic such as pharmaceutical firms, medical devices manufacturers rely heavily on healthcare facilities to obtain data from clinical trials. Most medical device products must pass pre and post-market clinical trials before manufacturers can receive regulatory approval certificates. While the COVID-19 pandemic continues, medical device companies struggle to make informed decisions about their products, supply chains, and regulatory responsibilities amid uncertainty. Announcements from the governing bodies and discussions with key decision makers and regulatory experts are critical to the medical device industry's success.
Browse 9 Market Data Tables and 26 Figures spread through 185 Pages and in-depth TOC on “U.K. Drug for Abuse Testing Devices Market”- Global Forecast to 2027, U.K. Drug for Abuse Testing Devices Market, by Product Type (Immunoassay Analyzers, Chromatography Instruments, Breathalyzers (Semi-Conductor-Based Breathalyzer, Infrared (IR) Based Breathalyzer, and Fuel Cell-Based Breathalyzer), Oral Fluid Testing Devices, Urine Testing Devices (Drug Testing Cup, DIP Cards, and Drug Testing Cassettes) , and Consumables (Assay Kits, Calibrators and Controls, and Others)), by Sample Type (Urine, Breathe, Saliva, Hair, and Others), and by End User (Hospitals, Federal Departments, Rehabilitation Centers, Diagnostic Laboratories, Academic Institutes and Research Centers, and Others), published by Coherent Market Insights.
To know the latest trends and insights prevalent in the U.K. Drug for Abuse Testing Devices Market, click the link below:
Key players in the market are involved in the launch of novel drugs for abuse testing devices. Hair and nail testing are majorly being used for detection of drug use history. Moreover, smartphone connected breathalyzers and innovative drug tests such as fingerprint test are expected to shift the market trend towards wearable drug testing devices. For instance, in March 2019, BACtrack introduced BACtrack View, the world's first smartphone-based remote alcohol monitoring system. BACtrack View is a novel, app-based alcohol monitoring service.
Key Takeaways of the U.K. Drug for Abuse Testing Devices Market:
- The U.K. drug for abuse testing devices market is expected to exhibit a CAGR of 5.0% during the forecast period, owing to increasing incidence drunk and drive cases, and drug addiction and this is further expected to drive the market growth during the forecast period. For instance, according to the National Health Service U.K. report published in August 2019, cannabis was the most commonly used drug by respondents in the 2018/19 Crime Survey for England and Wales, with 7.6% of adults aged 16 to 59 having used it in 2017-2018, equating to around 2.6 million people.
- Among product type, consumable segment accounted for the largest market share in U.K drug for abuse testing devices market in 2020, owing to increasing approval of novel products. For instance, in 2019, the U.K government granted the first license for a drug-testing clinic at Weston-super-Mare (U.K), where any individual in the U.K can submit illegal substances to be checked without fear of arrest. With launch of such labs will drive demand for consumables for conducting test, which expected to drive growth of the segment.
- On the basis of sample type, urine segment is expected to witness highest growth in the U.K. drug for abuse testing devices market in 2020. The urine segment is expected to witness significant growth over the forecast period due to the increasing incidence of opioid addiction and need for drug testing in places such as drug rehabilitation centers, workplace drug testing, and medico-legal situations require urine sample. On the other hand, in case of alcohol testing, urine testing is done only if other tests are not available, as urine testing cannot be conducted on the spot of the incident (traffic stop) and sample is affected, as the time passes.
Key players operating in the U.K drug for abuse testing devices include Abbott Laboratories, Thermo Fisher Scientific, Inc, Drägerwerk AG & Co. KGaA, Laboratory Corporation of America Holdings, Quest Diagnostics, Alfa Scientific Designs, Inc, Lifeloc Technologies Inc, Lion Laboratories Limited, OraSure Technologies, Inc, Omega Laboratories, Inc., Shimadzu Corporation, Siemens Healthineers, F. Hoffmann-La Roche AG, Premier Biotech, Inc, Psychemedics Corporation, Innovative Testing Solutions, Biopanda Reagents Ltd, Alpha Laboratories, Matrix Diagnostics, Atlas Medical, Rapid Labs Limited, and Randox Laboratories Ltd.